PBIM 2022 №6 (140)

Subject of the article

АСПЕКТЫ ГОРМОНОТЕРАПИИ В ЛЕЧЕНИИ РАКA МОЛОЧНОЙ ЖЕЛЕЗЫ С УЧЕТОМ БИОЛОГИЧЕСКИХ ПОДТИПОВ (331-334)

Authors

Алимходжаева Лола Тельмановна, Хасанов Комилжон Суннатуллаевич

Institution

Республиканский специализированный научно-практический медицинский центр онкологии и радиологии, Республика Узбекистан, г. Ташкент

Abstract

Пациенты с гормоночувствительным и Her2neu амплифицированным подтипом опухоли имеют лучший краткосрочный прогноз, чем больные с гормонотрицательными и Erb-B2 сверхэкспрессирую-щий подтипом. При гормоноположительном Люми-нальном А подтипе рака молочной железы (РМЖ) гормонотерапия является единственной системной терапией, приносящей пользу и должна применяться у больных, находящихся в хорошей физической форме.

Key words

рак молочной железы, таргетная, системная химиотерапия, гормонотерапия , люминальный А подтип, люминальный В подтип, протеин HER2.

Literature

1. Abe O. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. / Abe R, Enomoto K.// Lancet 2005. –V.365. –P 1687–1717 2. Albain K. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. /Anderson S, Arriagada R.// Lancet 2012. -V.379.-P 432–444 3. Burstein H J. American Society of Clinical On-cology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. / Prestrud A.A, Seidenfeld J.// J Clin.Oncol 2010.-V. 28.-P 3784–3796 4. Christman K. Chemotherapy of metastatic breast cancer in the elderly. / Muss H.B, Case L.D. //ThePiedmontOncologyAssociationexperience. JAMA 2012.-V. 268.-P 57–62 5. Diab S.G. Tumor characteristics and clinical outcome of elderly women with breast cancer. /Elledge R.M, Clark G.M. //JNatlCancerInst 2000. –V. 92. –P 550–556 6. Dowsett M. Prediction of risk of distant recur-rence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. /Cuzick J, Wale C.// JClinOncol 2010.-V.28.-P 1829–1834 7. Foulkes W. Triple-negativebreastcancer. /Smith I, Reis J.// NEnglJMed 2010.-V.363.-P 1938–1948 8. Freyer G. Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study. /Campone M, Peron J.// CritRevOncolHematol 2011.-V.80.-P 466–473 9. Geyer C. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. /Forster J, Lindquist D. //NEnglJMed 2006.-V.355.-P 2733–2743 10. Gregor M. Trastuzumab-related cardiotoxicity among older breast cancer patients. /Zhang N, Niu J. //ASCO Meeting Abstract. JClinOncol 2012.-V.30. -P 135 11. Jones S. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. / Holmes F, O’Shaughnessy J. // JClinOncol 2009. –V. 27. – P 1177–1183 12. Muss H. Investigators. Adjuvant chemotherapy in older women with early-stage breast cancer. /Berry D, Cirrincione C.// NEnglJMed 2010. –V. 360.-P 2055–2065 13. Paik S. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. / Tang G, Shak S. // JClinOncol 2006. –V.24.-P 3726–3734 14. Partridge A. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. / Archer L, Kornblith A. // JClinOncol 2010. –V. 28.-P. 2418–2422 15. Ravdin P. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. / Siminoff L, Davis G. // JClinOncol 2001. –V.19. –P. 980–991